•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now
S&P 500 Gains and Losses Today: Johnson & Johnson Stock Jumps; Universal Health Services Shares Slide
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
JNJ's Stock Price Is Back in Rally Mode—The Time to Buy Is Now
JNJ Technicals & Takeaways After Earnings, Healthcare Reaching Key Levels
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
2 Dividend Giants Every Passive Income Investors Should Own
Johnson & Johnson Lifts 2025 Outlook
Why Johnson & Johnson Rallied Today
Johnson & Johnson Stock Jumps on Strong Earnings, Higher Outlook
Johnson & Johnson Tops Q2 Estimates
Final Trades: Johnson & Johnson, ICE and the IBIT
Top Stock Movers Now: J&J, ASML, Tesla, and More
PPI Remained Unchanged
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
J&J CFO: We're pleased with the engagement with the Trump administration
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.